

20 March 2018

Market Announcements Office
ASX Limited
Level 4, North Tower, Rialto
525 Collins Street
Melbourne VIC 3000

Electronic Lodgement via ASX Online

Pro Medicus Limited (PME) – sell down by Co-Founders

The Company has been informed that Sam Hupert and Anthony Hall have sold 1,000,000 ordinary shares each in the capital of the Company. As a consequence, the remaining holdings of Sam Hupert are 29,107,660 ordinary shares in the capital of the Company, representing approximately 28.2% of the issued share capital of the Company.

The remaining holdings of Anthony Hall are 29,067,500 ordinary shares in the capital of the Company, representing approximately 28.1% of the issued capital of the Company.

Clayton Hatch
Company Secretary
Pro Medicus Limited

20 March 2018

Peter Kempen
Chairman
Pro Medicus Limited
450 Swan Street
Richmond VIC 3121

Clayton Hatch
Company Secretary
Pro Medicus Limited
450 Swan Street
Richmond VIC 3121

Dear Peter & Clayton,

Reduction of shareholding in Pro Medicus Limited (PME)

We are writing to inform you that we; Sam Hupert and Anthony Hall as shareholders have each sold 1,000,000 of our shares in PME in the last few days.

Our shareholding in PME on completion of the sale will be; Sam Hupert approximately 28.2% and Anthony Hall approximately 28.1% and we do not intend to sell any further shares in PME during the current trading period.

Yours faithfully,



Sam Hupert
CEO and Co-Founder
Pro Medicus Limited



Anthony Hall
Technology Director and Co-Founder
Pro Medicus Limited

20 March 2018

Market Announcements Office
ASX Limited
Level 4, North Tower, Rialto
525 Collins Street
Melbourne VIC 3000

Electronic Lodgement via ASX Online

Notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) (the Act)

Pro Medicus Limited (ASX Code: PME) (**Company**) refers to the announcement on 20 March 2018 in relation to the sale by Dr Sam Hupert of 1,000,000 shares in the Company and by Mr Anthony Hall of 1,000,000 shares in the Company.

This notice is given by the Company under section 708A(5)(e) of the Act (as modified by ASIC Instrument 2016/81).

The Company advises that:

- (a) Dr Hupert and Mr Hall sold the relevant securities in the Company without disclosure to investors under Part 6D.2 of the Act;
- (b) as at the date of this notice, the Company has complied with:
 - (i) the provisions of Chapter 2M of the Act as they apply to the Company; and
 - (ii) section 674 of the Act; and
- (c) as at the date of this notice, there is no "excluded information" for the purposes of subsections 708A(7) or (8) of the Act.

Yours faithfully,



Clayton Hatch
Company Secretary
Pro Medicus Limited

The Manager
Company Announcements Office
ASX Limited
Level 4, North Tower, Rialto
525 Collins Street
Melbourne VIC 3000

20 March 2018

Dear Sir/Madam

Pro Medicus Limited (ASX: PME) Sale offers within 12 months after controller sales

For the purposes of section 708A(5) and (6) of the *Corporations Act 2001* (Cth) (**Act**), as modified by ASIC Corporations (Sale Offers By Controllers) Instrument 2016/81, Sam Hupert and Anthony Hall (**Vendor**) gives notice under section 708A(5)(e) of the Act of the following details:

- (a) On 19 March 2018, the vendor executed the sale of 1,000,000 fully paid ordinary shares each (**Sale Shares**) in the issued capital of Pro Medicus Limited (**PME**) to a range of institutional investors;
- (b) the Vendor, as controllers of PME for the purposes of the Act at the date of the sale, sold the Sale Shares without disclosure to investors under Part 6D.2 of the Act;
- (c) as far as the Vendors are aware, as at the date of this notice, PME has complied with the provisions of Chapter 2M as they apply to PME and section 674 of the Act; and
- (d) the Vendor is not aware of any information that may be "excluded information" for the purposes of section 708A(7) or (8) of the Act, as at the date of this notice.

Issued by



Sam Hupert
CEO and Co-Founder
Pro Medicus Limited



Anthony Hall
Technology Director and Co-Founder
Pro Medicus Limited